Lepidine

Lepidine is a quinoline alkaloid found in plants such as Lepidium species, notable for its ability to modulate muscarinic receptors and act as a calcium channel antagonist. Its primary investigated mechanisms involve improving glycemic control and exerting bronchodilatory effects in preclinical animal models.

Origin & History

Lepidine is a natural alkaloid isolated from the seeds of Lepidium sativum, commonly known as garden cress. It is part of the quinoline alkaloids and is typically extracted using solvent methods such as hexanic extraction.

Historical & Cultural Context

Lepidium sativum has traditional use in treating airway disorders such as cough and asthma, supported by its bronchodilatory mechanisms. Specific historical systems using lepidine are not documented.

Health Benefits

• May reduce fasting blood glucose and improve lipid profiles in diabetic rat models, enhancing pancreatic islet function (Preclinical study)[2]. • Shows potential bronchodilatory activity by inhibiting muscarinic receptors and acting as a Ca²⁺ antagonist in guinea-pig trachea (Animal study)[4]. • Exhibits antifungal properties by inhibiting enzymes in Candida albicans (In vitro study)[6]. • Inhibits enzymes linked to Alzheimer's and SARS-CoV-2, though evidence is limited to in silico and in vitro studies (In vitro study)[5][6]. • Potentiates the effects of metformin in diabetic rat models, indicating possible adjunctive benefits (Preclinical study)[2].

How It Works

Lepidine exerts bronchodilatory effects by antagonizing muscarinic (M3) receptors in airway smooth muscle and functioning as a Ca²⁺ channel antagonist, reducing intracellular calcium-mediated bronchoconstriction in guinea-pig tracheal tissue. In diabetic animal models, lepidine appears to enhance pancreatic beta-cell function and insulin secretion, thereby improving fasting blood glucose and lipid profiles. These dual mechanisms suggest interactions with cholinergic signaling pathways and glucose homeostasis regulators, though the precise molecular targets in human physiology remain uncharacterized.

Scientific Research

No human clinical trials or meta-analyses specifically on lepidine have been found. The evidence is largely limited to preclinical studies in animal models and in vitro experiments.[2][4][6]

Clinical Summary

Current evidence for lepidine is entirely preclinical, derived from in vitro and animal studies, with no published human clinical trials as of 2024. Diabetic rat model studies have reported reductions in fasting blood glucose and improvements in lipid profiles, alongside enhanced pancreatic islet morphology and function. Guinea-pig tracheal preparations have demonstrated measurable bronchodilatory responses attributed to muscarinic receptor antagonism and calcium antagonism. The absence of human data means efficacy and appropriate dosing in humans cannot be established, and all findings should be interpreted with significant caution.

Nutritional Profile

Lepidine (4-methylquinoline, C₁₀H₉N, MW 143.19 g/mol) is a heterocyclic aromatic nitrogen compound, not a nutrient or food item. It is a synthetic/naturally occurring quinoline derivative and is classified as a bioactive chemical compound rather than a source of macro- or micronutrients. Key details: • It is a colorless to pale yellow liquid with a boiling point of ~262°C and density ~1.086 g/cm³. • It contains no vitamins, minerals, dietary fiber, or protein. • It has no caloric or nutritional value for human consumption. • As a bioactive compound, its pharmacologically relevant concentrations in research are typically in the micromolar (µM) range: antifungal MIC values reported against Candida albicans in the range of ~50–200 µg/mL (in vitro); bronchodilatory effects observed at concentrations of ~10⁻⁶–10⁻⁴ M in isolated tissue preparations; hypoglycemic effects in diabetic rat models studied at oral doses of ~20–50 mg/kg body weight. • Lepidine and its derivatives (e.g., lepidine N-oxide, chlorolepidine) serve primarily as scaffolds in medicinal chemistry for synthesizing pharmacologically active analogs. • Bioavailability: Limited human pharmacokinetic data exist. In animal models, quinoline derivatives including lepidine are generally absorbed orally and undergo hepatic metabolism via cytochrome P450 enzymes (particularly CYP1A2 and CYP3A4), yielding hydroxylated and N-oxidized metabolites. Lipophilicity (logP ~2.0–2.5) suggests moderate membrane permeability. • Naturally found in small trace amounts in coal tar and certain plant alkaloid fractions, but not at nutritionally meaningful concentrations. • Safety note: Quinoline derivatives can exhibit hepatotoxicity and mutagenic potential at elevated doses; lepidine is not approved for human dietary or therapeutic use.

Preparation & Dosage

No clinically studied dosages in humans exist. In preclinical rat studies, lepidine was dosed at 20 mg/kg body weight orally every other day for 4 weeks. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Metformin, Atropine, Verapamil, Isoprenaline, Rolipram

Safety & Interactions

No human safety data, established safe dosage ranges, or toxicology profiles exist for lepidine as an isolated supplement ingredient. Given its muscarinic receptor antagonist activity, theoretical interactions with anticholinergic drugs (e.g., atropine, tiotropium) and potential additive effects on heart rate or intraocular pressure are plausible concerns. Its reported blood glucose-lowering activity in animal models suggests a theoretical risk of additive hypoglycemia when combined with antidiabetic medications such as metformin or insulin. Lepidine should be avoided during pregnancy and lactation due to a complete absence of safety data in these populations.